Department of Obstetrics and Gynecology, Women & Infants Hospital of Zhengzhou, Zhengzhou, China.
Eur Rev Med Pharmacol Sci. 2020 Feb;24(4):1666-1671. doi: 10.26355/eurrev_202002_20340.
To explore the expression of Stomatin-like protein 2 (SLP-2) and its clinical significance in epithelial ovarian cancer (EOC).
Quantitative real-time polymerase chain reaction (qRT-PCR) was used to detect the differential expression of SLP-2 in EOC tissues and cell lines. The relationship between SLP-2 expression and clinical pathological data of EOC patients was analyzed.
QRT-PCR results suggested that the SLP-2 was up-regulated in both EOC tissues and EOC cells by comparing with normal control. SLP-2 expression was a correlation with tumor pathological grade, distant metastasis, and TNM stage in EOC patients. Down-regulation of SLP-2 could significantly inhibit proliferation and promote apoptosis of EOC cells by activating the Notch signaling pathway. Knockdown of SLP-2 markedly downregulated Notch1 and Hes1.
SLP-2 was a novel factor involved in EOC progression, and could be utilized as a potential biomarker and therapeutic target for the EOC patients.
探讨 Stomatin-like 蛋白 2（SLP-2）在卵巢上皮性癌（EOC）中的表达及其临床意义。
采用实时荧光定量聚合酶链反应（qRT-PCR）检测 SLP-2 在 EOC 组织和细胞系中的差异表达。分析 SLP-2 表达与 EOC 患者临床病理资料的关系。
与正常对照组相比，qRT-PCR 结果表明 SLP-2 在 EOC 组织和细胞中均上调。SLP-2 的表达与 EOC 患者的肿瘤病理分级、远处转移和 TNM 分期相关。下调 SLP-2 可通过激活 Notch 信号通路显著抑制 EOC 细胞的增殖并促进其凋亡。SLP-2 的敲低显著下调 Notch1 和 Hes1。
SLP-2 是参与 EOC 进展的新型因子，可作为 EOC 患者的潜在生物标志物和治疗靶点。
